Page 14 - Sun Pharma
We thrive on products that have limited competition: Top Sun Pharma execs
In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic
 "We thrive on products that have limited competition: Top Sun Pharma execs")
Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales
Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year
 "Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales")
Sensex gains 375 pts, ends above 61K; Nifty atop 18,100; IT, metal lead
MARKET WRAP: Pharma, power and IT stocks were the major gainers in trade on Tuesday, while index heavyweight Reliance Industries and select banking shares ended on a tepid note.
 "Sensex gains 375 pts, ends above 61K; Nifty atop 18,100; IT, metal lead")
Sun Pharma extends gains post September quarter earnings; up 6% in two days
The management said the strong revenue and margins were driven by market share gain in India, sustained ramp-up of the company's global specialty business and growth in Emerging Markets
 "Sun Pharma extends gains post September quarter earnings; up 6% in two days")
Pharma shares may turnaound soon; Cipla, Sun Pharma, Granules can gain 20%
What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.
 "Pharma shares may turnaound soon; Cipla, Sun Pharma, Granules can gain 20%")
Sun Pharma gains 2%, conquers Rs 1,000-mark after gap of over 7 years
The stock traded higher for the third straight day and has gained nearly 4 per cent during the period. It quoted at its highest level since May 2015.
 "Sun Pharma gains 2%, conquers Rs 1,000-mark after gap of over 7 years")
Nifty500: 248 stocks have more upside; Sun Pharma, RITES 'overbought'
Sun Pharmaceutical Industries is the only other stock among the Sensex 30 and Nifty 50 that trades in the overbought category, technically.
 "Nifty500: 248 stocks have more upside; Sun Pharma, RITES 'overbought'")
Supreme Court rejects plea by Hero MotoCorp for full budgetary support
But suggests GST Council, states consider mechanism for reimbursing eligible units
 "Supreme Court rejects plea by Hero MotoCorp for full budgetary support")
Suzlon Energy looks to pare debt by Rs 583.5 crore after rights issue
Targets repaying remaining debt in eight years; Rs 1,200 crore opened on Tuesday
 "Suzlon Energy looks to pare debt by Rs 583.5 crore after rights issue")
Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%
The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it
 "Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%")
Nifty Pharma outshines benchmarks, up 2%; Cipla, Sun Pharma hit 52-wk highs
Shares of Glenmark Pharma, Granules India, Divi's Laboratories, Torrent Pharma, Lupin and Aurobindo Pharma, surged in the range of 2 per cent to 6 per cent in Monday's intra-day trade
LIC, Nykaa, Tata Motors: Are these buzzing stocks bottoming out?
Sun Pharmaceutical seems set to register a new 52-week high; while Tata Motors and Torrent Pharmaceuticals are yet to take-off their respective obstacles, charts show.
 "LIC, Nykaa, Tata Motors: Are these buzzing stocks bottoming out?")
Sun Pharma extends rally, surges 7% in two days; now trades at 5-month high
Sun Pharma could see structural growth and be relatively insulated from the adverse price erosion scenario in the US, according to analysts.
Rise of cosmetic dermatology space gets big pharma looking for buyouts
According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.
 "Rise of cosmetic dermatology space gets big pharma looking for buyouts")
Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025
The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021
 "Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025")
Six-day work weeks won't work anymore for new talent, says report
According to a report, companies with 6-day work weeks have to settle for leftover talent
 "Six-day work weeks won't work anymore for new talent, says report")
Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US
Leading generic drug makers Glenmark, Sun Pharma, Dr Reddy's and Jubilant Cadista are recalling multiple products in the US market, the world's largest market for medicines, for various issues
 "Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US")
Sun Pharma stock likely to keep shining amid global specialty scale-up
Focus on key markets to help expand branded formulations business, say experts
 "Sun Pharma stock likely to keep shining amid global specialty scale-up")
We continue to increase our reach and access in India, say Sun Pharma execs
Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more
 "We continue to increase our reach and access in India, say Sun Pharma execs")
Sun Pharma Q1 net up 43% to Rs 2,061 crore on specialty sales, India biz
Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%